ArticleClinical medicine insights. Circulatory, respiratory and pulmonary medicine2011
Optimal management of severe/refractory asthma.
Article in Clinical medicine insights. Circulatory, respiratory and pulmonary medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effect of physical training on airway inflammation in bronchial asthma: a systematic review.BMC pulmonary medicine · 2013Pooled it
- Treatment by biomarker-informed endotype vs guideline care in children with difficult-to-treat asthma.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2022Trial
- Type 2 asthma paediatric patients eligible for dupilumab: An Italian biomarker-based analysis.The World Allergy Organization journal · 2024Article
- Biomarkers of type 2 and non-type 2 inflammation in asthma exacerbations.Central-European journal of immunology · 2024Article
- Defining type 2 asthma and patients eligible for dupilumab in Italy: a biomarker-based analysis.Clinical and molecular allergy : CMA · 2021Article
- Immunologic Pathophysiology and Airway Remodeling Mechanism in Severe Asthma: Focused on IgE-Mediated Pathways.Diagnostics (Basel, Switzerland) · 2021Review
- Cost-effectiveness of fractional exhaled nitric oxide (FeNO) measurement in predicting response to omalizumab in asthma.ClinicoEconomics and outcomes research : CEOR · 2019Article
- Efficacy and steroid-sparing effect of benralizumab: has it an advantage over its competitors?Drugs in context · 2019Review
- Nanoparticle-based CpG-oligonucleotide therapy for treating allergic asthma.Immunotherapy · 2018Review
- Severe refractory asthma: current treatment options and ongoing research.Drugs in context · 2018Review
- Omalizumab for Severe Asthma: Beyond Allergic Asthma.BioMed research international · 2018Review
- Central Role of IL-23 and IL-17 Producing Eosinophils as Immunomodulatory Effector Cells in Acute Pulmonary Aspergillosis and Allergic Asthma.PLoS pathogens · 2017Article
- Measurement of utility in asthma: evidence indicating that generic instruments may miss clinically important changes.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2016Article
- A long-acting β2-adrenergic agonist increases the expression of muscarine cholinergic subtype‑3 receptors by activating the β2-adrenoceptor cyclic adenosine monophosphate signaling pathway in airway smooth muscle cells.Molecular medicine reports · 2015Article
- Refractory asthma treatment is complicated by tracheobronchomalacia: case reports and review of the literature.Case reports in medicine · 2013Article
- Inflammatory marker sTREM-1 reflects the clinical stage and respiratory tract obstruction in allergic asthma bronchiale patients and correlates with number of neutrophils.Mediators of inflammation · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma is a chronic inflammatory disease of the airways, affecting approximately 300 million people worldwide. Asthma results in airway hyperresponsiveness, leading to paroxysmal symptoms of wheeze, cough, shortness of breath, and chest tightness. When these symptoms remain uncontrolled, despite treatment with high doses of inhaled and ingested corticosteroids, asthmatic patients are predisposed to greater morbidity and require more health care support. Treating patients with severe asthma can be difficult and often poses a challenge to physicians when providing ongoing management. This clinical review aims to discuss the definition, prevalence and evaluation of severe asthmatics, and provides a review of the existing pharmacologic and non-pharmacologic treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.